Abstract: Aspects of the disclosure relate to multimeric molecules and methods of producing the same. In some embodiments, the multimeric molecules comprise at least two nucleic acid molecules (e.g., mRNA molecules) joined by non-covalent bonds between non-coding regions.
Abstract: The inhibitory oligonucleotides with partial phosphorothioation with reduced toxicity strongly block NF-kB activation induced by TLR9 agonists and TLR7/8 agonists. The production of proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFa), is inhibited by the inhibitory-oligonucleotides. Interferon (IFN) production from human PBMC induced by TLR9 agonist is prevented by the inhibitory-oligonucleotides. These oligonucleotides can be used as a remedy for the treatment of immune-mediated disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes and inflammatory cytokine-mediated inflammatory disease.
Abstract: Provided is a preparation to be applied to an ophthalmic device comprising a cinnamic acid derivative, the application of which to the ophthalmic device can ameliorate symptoms on the ocular surface or prevent damage on the ocular surface.
Abstract: Compositions and methods are for combating inflammatory disease and particularly for use in feed or food compositions for preventing, reducing and/or treating inflammatory disorders, diseases, or discomforts. The compositions include at least one specific pectin.
Type:
Application
Filed:
July 8, 2016
Publication date:
January 10, 2019
Inventors:
Geert Bruggeman, Erik Bruininx, Marco Van Den Berg, Paulus De Vos, Neha Mohan Sahasrabudhe, Antonius Johannes Willibrordus Scheurink, Hendrik Arie Schols, Jan Scholte, Lingmin Tian
Abstract: The present invention relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, and a pharmaceutically acceptable carrier, and which can be stored at room temperature. The present invention also relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, sorbitol, and a pharmaceutical acceptable carrier.
Type:
Application
Filed:
January 27, 2017
Publication date:
January 10, 2019
Applicant:
SEIKAGAKU CORPORATION
Inventors:
Eiji NOGAMI, Akira KOUSHINBOU, Noriko OSHIMA, Kota FUJIWARA, Tomoya SATO
Abstract: Disclosed herein are pharmaceutical salts of a cationic protonated polyamine pharmaceutical agent and an anionic organic carboxylate which is hydrophobic when in protonated form, particularly suited for oral administration, where these salts have good bioavailability in solid dosage forms and may be used in the treatment of cancer and other medical conditions for which the pharmaceutical agent is intended.
Abstract: The present invention relates to a composition comprising a mixture of a polymeric biguanide polymer and an alkyl and/or dialkyl oxyethylene methyl ammonium salt for use as a medicament, in particular for use in treating, preventing or ameliorating a fungal disease such as aspergillosis. The present invention provides a method of treating, preventing and/or ameliorating a medical condition comprising administering the composition of the present invention to a human or animal in need thereof. A mechanical device comprising said composition is also provided.
Abstract: The present invention relates to methods and compositions of treating patients suffering from, or at risk for, DNA damage and to increase life span, i.e., prevent or slow the aging process in all species. The treatment includes administering to the patient a pharmaceutical composition that includes carbon monoxide.
Abstract: This invention describes an cellular and subcellular “social network” at a biomolecular level that provides systems and methods for life extension, disease prevention and cellular rejuvenation through the transfer or exchange of biochemical, electrophysiological and sub-cellular biomolecular constructs and/or their assemblies, either in their totality or in part as carriers of material and/or information through interactions and continuous intercourses between neighboring cells. First responder cells are engineered or primed to support such conveyances including, but not limited to: organelles, macromolecules, lipids, ions, etc. from cells able to dispose of said biomaterials, etc. to cells requiring or standing to benefit therefrom. Among other advantages, these systems and methods provide increased capacity for managing intact mitochondrial (switching) mechanisms for the restoration or improved functionality of compromised cells.
Abstract: Constructs are provided that exploit selected portions of the TLR4 receptor to which no extracellular ligand will bind. A dimerization domain is employed to allow for regulated activation when used in conjunction with a dimerizer drug. In addition, a myristoylation domain facilitates intracellular presentation. Constructs of the invention can be used to create engineered monocytes whose TLR4 receptors can be selectively activated with administration of a dimerization agent. Engineered macrophages can be selectively induced to become pro-inflammatory, providing methods to ameliorate conditions associated with excessive pro-repair macrophages, such as cardiac fibrosis and solid tumor growth. Delivery of the engineered macrophages to sites of cardiac fibrosis can reduce the amount of fibrosis and scarring and ameliorate cardiac function. Delivery of the engineered macrophages to solid tumors can reduce tumor growth and size.
Type:
Application
Filed:
July 22, 2016
Publication date:
January 10, 2019
Applicant:
UNIVERSITY OF WASHINGTON
Inventors:
Marta SCATENA, Karen EATON, Cecilia M. GIACHELLI
Abstract: The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DGK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.
Type:
Application
Filed:
February 28, 2018
Publication date:
January 10, 2019
Inventors:
Steven M. ALBELDA, Liang-Chuan WANG, Gary KORETZKY, Matthew RIESE
Abstract: Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.
Type:
Application
Filed:
April 6, 2018
Publication date:
January 10, 2019
Inventors:
Branden MORIARITY, Beau WEBBER, Modassir CHOUDHRY, Steven A. ROSENBERG, Douglas C. PALMER, Nicholas P. RESTIFO
Abstract: Compositions for inducing immune tolerance and methods to modify antigen to treat disease such as autoimmune diseases and allergy are described. The compositions and related methods comprise APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to antigen. The compositions can be particle containing antigen and immunosuppressant. The compositions can also be linear polymer containing antigen and immunosuppressant.
Abstract: A pharmaceutical composition includes an effective amount of a bio-active fraction or subfraction of lyophilized camel urine. The composition is used as an anti-cancer drug which selectively targets the cancer cells without affecting the normal cells.
Abstract: This disclosure relates to populations and compositions of purified cell-derived vesicles and uses thereof. One aspect of the disclosure relates to methods for purifying the cell-derived vesicles.
Type:
Application
Filed:
December 30, 2016
Publication date:
January 10, 2019
Inventors:
Johnathon D. ANDERSON, Jan A. NOLTA, Gerhard BAUER, Brian FURY
Abstract: An acellular soft tissue-derived matrix includes a collagenous tissue that has been delipidated and decellularized. Adipose tissue is among the soft tissues suitable for manufacturing an acellular soft tissue-derived matrix. Exogenous tissuegenic cells and other biologically-active factors may be added to the acellular matrix. The acellular matrix may be provided as particles, a slurry, a paste, a gel, or in some other form. The acellular matrix may be provided as a three-dimensional scaffold that has been reconstituted from particles of the three-dimensional tissue. The three-dimensional scaffold may have the shape of an anatomical feature and serve as a template for tissue repair or replacement. A method of making an acellular soft tissue-derived matrix includes steps of removing lipid from the soft tissue by solvent extraction and chemical decellularization of the soft tissue.
Type:
Application
Filed:
September 5, 2018
Publication date:
January 10, 2019
Inventors:
Yen-Chen Huang, Asia Ivery, Bryan Choi, Benjamin Schilling, Manh-Dan Ngo
Abstract: The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
Type:
Application
Filed:
September 7, 2018
Publication date:
January 10, 2019
Applicant:
United Therapeutics Corporation
Inventors:
Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
Abstract: A composition including a mixture of at least two different honeys is used to treat a variety of medical conditions. The composition can be administered topically, orally, by inhalation or parenterally. The composition is useful in treating wounds, infections, diabetes, skin conditions, renal conditions, dehydration, malnutrition, hypertension and various other conditions. It has been found that the mixture of at least two different types of honey, either alone or in combination with other bee products is more effective than the administration of single honey.
Abstract: A composition including a mixture of at least two different forms of propolis is used to treat a variety of medical conditions. The composition can be administered topically, orally, by inhalation or parenterally. The composition is useful in treating wounds, infections, diabetes, skin conditions, renal conditions, dehydration, malnutrition, hypertension and various other conditions. It has been found that the mixture of at least two different types of propolis, either alone or in combination with other natural products is more effective than the administration of single propolis.
Abstract: A composition including a mixture of honey, curcumin, propolis or CAPE or any two of them is used to treat a variety of medical conditions. The composition can be administered topically, orally, by inhalation or parenterally. The composition is useful in treating wounds, infections, diabetes, skin conditions, renal conditions, dehydration, malnutrition, hypertension and various other conditions. The mixture of honey, curcumin, and propolis or CAPE, either alone or in combination with other natural products is more effective than the administration of single ingredient.
Abstract: The invention provides compositions comprising one or more bacterial strains for use in a method of reducing the level of Enterobacteriaceae in the gastrointestinal tract.
Abstract: The present invention relates to means and method for AAV based gene therapies in humans. In particular, the present invention relates to the treatment of human patients that may be suspected to have antibodies directed against the AAV intended for use in the treatment.
Type:
Application
Filed:
July 10, 2018
Publication date:
January 10, 2019
Applicant:
uniQure IP B.V.
Inventors:
Bart Antonius NIJMEIJER, Valerie FERREIRA
Abstract: The present invention provides a method of increasing the growth of staphylococcus epidermidis on skin, comprising topically applying to skin in need of treatment for eczema, acne, decreased moisturization, or other skin conditions associated with microbiota dysbiosis a composition comprising an extract of Pichia anomala and glycerin.
Abstract: The present invention discloses the Cordyceps cicadae mycelia, the active substances of C. cicadae mycelia, its submerged fermentation product and its pharmaceutical composition for preventing, delaying or treating cataracts, and the methods for preparing the products above. The C. cicadae mycelia, the active substances of C. cicadae mycelia, its submerged fermentation product and its pharmaceutical composition further can be prepared as a health food for preventing or delaying cataracts.
Abstract: Many people who suffer from anal rectal discomfort and disorders need fibrous sheet materials which are pre-moistened with a solution for improved cleansing without excessive skin irritation. The invention particularly concerns wet wipes, such as anal-rectal wipes, which comprises a solution comprising hamamelis water or witch hazel, to effectively treat anal-rectal disorders.
Type:
Application
Filed:
September 12, 2018
Publication date:
January 10, 2019
Inventors:
Gary Robert Agisim, Robert Alan Friedline, Richard John Kenny
Abstract: Disclosed are treatment compositions adapted for application to mammalian skin, which treatment compositions are effective initiators for the generation of human keratinocytes on or within the treated skin, particularly in the locus of the skin wherein the treatment composition has been applied, which treatment composition comprises benzoin and an olive oil extract which contains hydroxytyrosol and/or hydroxytyrosol. In certain preferred embodiments the benzoin and the olive oil extract and/or hydroxytyrosol are microencapsulated.
Abstract: The invention discloses a black Chinese wolfberry effervescent tablet and a preparation method thereof. The preparation method comprises the following steps: 1. lyophilized powder of black Chinese wolfberry extract and part of citric acid are crushed and mixed; 2. the crushed and mixed material is taken out, added with a water-soluble starch and mixed again, and the resulting mixture is prepared into a soft material by taking ethanol as a wetting agent, then prepared into granules and dried until the water content is controlled at 2.2-3.5%; and 3. the granules prepared in step 2 are mixed with an alkali source, the remaining citric acid, sucrose and an encapsulant and then pressed into effervescent tablets.
Abstract: A therapeutic method for treating diabetes mellitus, particularly diabetes caused by pancreatitis, comprising administering an effective amount of a Chinese herbal medicine to a subject. The Chinese herbal medicine is an extract of a mixture comprising specific amount of raw oyster shell powder, raw Os Draconis, Haematitum, Magnetitum, radix Achyranthis Bidentatae, rhizoma Dioscoreae, radix Paeoniae Rubra, radix Rehmanniae, semen Platycladi, Coptidis Rhizoma, cortex Mori, rhubarb, and Davallia formosana.
Abstract: The present invention is directed to a therapeutic method of treatment of diabetes mellitus, particularly diabetes which acquires multiple drug resistance, comprising administering a therapeutically effective amount of Chinese herbal medicine to a subject in need. The Chinese herbal medicine is the decocting extract including the mixture of raw oyster shell powder, raw Os Draconis, Haematitum, Magnetitum, radix Achyranthis Bidentatae, rhizoma Dioscoreae, radix Paeoniae Rubra, radix Rehmanniae, and semen Platycladi.
Abstract: The present invention is directed to a therapeutic method of treatment of diabetes mellitus, particularly diabetes which acquires insulin resistance, comprising administering a therapeutically effective amount of Chinese herbal medicine to a subject in need. The Chinese herbal medicine is the decocting extract including the mixture of raw oyster shell powder, raw Os Draconis, Haematitum, Magnetitum, radix Achyranthis Bidentatae, rhizoma Dioscoreae, radix Paeoniae Rubra, radix Rehmanniae, and semen Platycladi.
Abstract: The present disclosure provides a novel combination of a NOD2 agonist with an immunotherapeutic agent for the treatment of cancer. The disclosure also comprises methods of treatments wherein a pharmaceutical composition of NOD2 agonist is used in combination with an immunotherapeutic agent. A pharmaceutical composition comprises of NOD2 agonist and an immunotherapeutic agent comprising PD-1 axis antagonist or CTLA4 antagonist with a pharmaceutically acceptable diluent or carrier.
Abstract: ETA receptor antagonists and methods of using the same to treat cardiovascular disorders and disease. In a method of treating a cardiovascular disease, the method includes the step of administering a therapeutically-effective amount of an endothelin type A (ETA) receptor antagonist to a mammal having the cardiovascular disease to treat the cardiovascular disease. An exemplary ETA receptor antagonist is BQ-123.
Abstract: The present invention relates to an ophthalmic composition comprising at least two active pharmaceutical ingredients. In particular, the active pharmaceutical ingredients are selected from the group consisting of: an alpha 2 adrenergic receptor agonist; a beta-adrenergic receptor agonist; an immunosuppressant; a lymphocyte associated antigen antagonist; an anti-inflammatory; a beta-blocker; a prostaglandin analog; a histamine receptor antagonist; a carbonic anhydrase inhibitor; and an antibiotic. In some embodiments, the composition of the invention is a nanoemulsion formulation. In one particular embodiment, the first active pharmaceutical ingredient is an alpha 2 adrenergic receptor agonist. The present invention also provides a method for treating various clinical conditions associated with an eye disorder or eye disease using the composition of the invention.
Abstract: Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panx1 hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein.
Type:
Application
Filed:
August 3, 2016
Publication date:
January 10, 2019
Applicant:
The Feinstein Institute For Medical Research
Inventors:
Haichao Wang, Wei Li, Kevin J. Tracey, Ping Wang
Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that masks or otherwise blocks phosphatidylserine on the pathogen cell surface.
Abstract: The present invention provides processes for producing porous silk fibroin scaffold material. The porous silk fibroin scaffold can be used for tissue engineering. The porosity of the silk fibroin scaffolds described herein can be adjusted as to mimic the gradient of densities found in natural tissue. Accordingly, methods for engineering of 3-dimensional tissue, e.g. bone and cartilage, using the silk fibroin scaffold material are also provided.
Type:
Application
Filed:
May 17, 2018
Publication date:
January 10, 2019
Inventors:
David L. Kaplan, Rina Sears, Gordana Vunjak-Novakovic, Lorenz Meinel
Abstract: The invention relates generally to compositions and methods for generating immunotolerant responses in a subject. Specifically, the invention relates to a composition comprising a sulfated polysaccharide and a bioactive polypeptide for generating an immunotolerant response.
Type:
Application
Filed:
January 5, 2017
Publication date:
January 10, 2019
Applicant:
B. G. Negev Technologies and Applications Ltd., at Ben-Gurion University
Abstract: Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
Type:
Application
Filed:
July 16, 2018
Publication date:
January 10, 2019
Applicant:
InCube Labs, LLC
Inventors:
Mercedes Morales, Mir Imran, Radhika Korupolu, Mir Hashim
Abstract: Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
Type:
Application
Filed:
August 24, 2018
Publication date:
January 10, 2019
Applicant:
InCube Labs, LLC
Inventors:
Mercedes Morales, Mir Imran, Radhika Korupolu, Mir Hashim
Abstract: Methods and compositions for the enzymatic debridement of wounds are provided. Methods for preparing enzymatic debridement compositions are also provided. In one embodiment, an enzymatic debridement composition prepared by dissolving crude bromelain in a composition comprising a weak acid, and filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition is provided.
Abstract: Methods of inhibiting or reducing tumor metabolism and growth are disclosed. A composition containing oxygen scavenging membrane fragments is administered within a tumor to create a hypoxic environment. This interferes with tumor growth and metabolism, and can lead to tumor death.
Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Type:
Application
Filed:
May 8, 2018
Publication date:
January 10, 2019
Inventors:
Timothy Z. Vitalis, Reinhard Gabathuler
Abstract: Certain aspects of the invention relate to methods for preventing or treating a skin condition in a subject, comprising administering a composition comprising a lysterase to the subject. Some aspects of the invention relate to pharmaceutical compositions comprising a lysterase. Some aspects of the invention relate to methods for producing a pharmaceutical composition, comprising expressing a lysterase in a recombinant cell and purifying the lysterase.
Type:
Application
Filed:
July 28, 2016
Publication date:
January 10, 2019
Inventors:
Robert L. Modlin, Graham F. Hatfull, Dominique J. Bardeau, Anil K. Ojha
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.
Type:
Application
Filed:
September 20, 2018
Publication date:
January 10, 2019
Inventors:
Robert Kotin, Adrian Philip Kells, Bernard Ravina
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.
Type:
Application
Filed:
September 20, 2018
Publication date:
January 10, 2019
Inventors:
Robert Kotin, Adrian Philip Kells, Bernard Ravina
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.
Type:
Application
Filed:
September 20, 2018
Publication date:
January 10, 2019
Inventors:
Robert Kotin, Adrian Philip Kells, Bernard Ravina
Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomoleules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.
Type:
Application
Filed:
August 20, 2018
Publication date:
January 10, 2019
Applicant:
New England Biolabs, Inc.
Inventors:
Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
Abstract: The application provides methods of treating a subject suffering from advanced-stage GvHD with ?1-antitrypsin (AAT), any carboxy terminal peptide derivatives thereof, or any recombinant versions thereof. In certain embodiments, the subject is a glucocorticoid-refractory patient having GvHD with gut involvement. In other embodiments, donor subjects of a transplant are treated with AAT, any carboxy terminal peptide derivatives thereof, or any recombinant versions thereof, to reduce graft rejection or GvHD in a recipient subject.
Type:
Application
Filed:
December 30, 2016
Publication date:
January 10, 2019
Inventors:
CHARLES DINARELLO, MARIO Q. MARCONDES, H. JOACHIM DEEG
Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.